PT-141 vs Melanotan II: Melanocortin Peptides Research Comparison
PT-141 was derived from Melanotan II research and then engineered for selectivity. Where Melanotan II activates the full spectrum of melanocortin receptors — producing tanning, appetite suppression, and sexual effects — PT-141 specifically targets the receptors responsible for central arousal. Here is what the research actually shows.
PT-141
Bremelanotide — FDA approved
- ✓FDA-approved (Vyleesi) for HSDD in women
- ✓Selective MC3R/MC4R — no tanning
- ✓Central dopamine pathway activation
- ✓Phase 3 data in both male and female subjects
- ✓~2.7 hr half-life
Melanotan II
Non-selective MCR agonist
- ✓Activates MC1R, MC3R, MC4R, MC5R
- ✓Strong systemic tanning (MC1R)
- ✓Appetite suppression (MC4R)
- ✓Sexual effects at lower doses
- ✓Never FDA approved
Side-by-Side Comparison
| Factor | PT-141 | Melanotan II |
|---|---|---|
| Chemical Class | Cyclic heptapeptide (Bremelanotide) | Cyclic heptapeptide (non-selective MCR agonist) |
| Receptor Targets | MC3R, MC4R (selective) | MC1R, MC3R, MC4R, MC5R (non-selective) |
| FDA Approval | Yes — approved 2019 as Vyleesi for HSDD | No — never FDA approved |
| Primary Research Use | Female and male sexual dysfunction | Tanning, appetite suppression, sexual effects |
| Tanning Effect | None — lacks MC1R activity | Strong — MC1R activation produces systemic tanning |
| Sexual Arousal Mechanism | Central — dopamine pathway in nucleus accumbens / MPOA | Central — similar MC3R/MC4R activation plus broader effects |
| Appetite Suppression | Minimal — limited MC4R-mediated appetite effect at standard doses | Significant — MC4R activation reduces appetite noticeably |
| Typical Research Dose | 1.25–1.75 mg SC | 250–500 mcg SC (lower doses than PT-141) |
| Half-Life | ~2.7 hours | ~1–2 hours |
| Selectivity | High — purpose-engineered for MCR selectivity | Low — broad melanocortin agonist |
Understanding Melanocortin Receptor Selectivity
PT-141: Engineered Selectivity
PT-141 was developed when researchers studying Melanotan II observed that the sexual arousal effects were mediated specifically by MC3R and MC4R — not MC1R (tanning) or MC5R (exocrine glands). PT-141 was engineered to retain MC3R/MC4R potency while losing MC1R activity.
The result is a compound that activates dopamine release in the nucleus accumbens and hypothalamic pathways (medial preoptic area) — producing arousal centrally without systemic tanning, significant appetite suppression, or MC5R-related effects.
This selectivity is what enabled PT-141 to enter Phase 3 clinical trials and ultimately receive FDA approval as Vyleesi in 2019 — the first approved treatment for female hypoactive sexual desire disorder.
Melanotan II: The Full Spectrum
Melanotan II is a non-selective melanocortin agonist that activates all five MCR subtypes. MC1R on melanocytes produces melanin synthesis and systemic tanning even without UV exposure. MC4R activation produces both sexual effects and appetite suppression — often simultaneously.
This broad receptor profile produces a wider range of effects per injection. Researchers studying combined outcomes (tanning + arousal, or appetite suppression + arousal) often use Melanotan II. However, the non-selective profile also means more variables to control.
Melanotan II also has a shorter half-life than PT-141 and is active at lower doses — 250–500 mcg versus PT-141's 1.25–1.75 mg — because it activates more receptor targets per molecule.
Which Peptide for Which Research Goal?
Sexual Health Research
FDA-approved mechanism, Phase 3 clinical data, selective MC3R/MC4R without confounding MC1R effects.
Skin Tanning Research
Only melanocortin peptide with direct MC1R agonism, producing systemic melanogenesis independent of UV.
Combined Tanning + Sexual Effects
Single compound covers both mechanisms simultaneously — no separate administration required.
Appetite Suppression Research
Stronger MC4R-mediated appetite suppression at typical doses; PT-141 doses are too low for significant appetite effects.
Regulatory-Clean Protocol
FDA-approved compound with clear clinical trial backing. Melanotan II has no approved indication anywhere.
Isolated CNS Arousal Study
Selective receptor profile means confounding systemic effects (tanning, appetite) are minimised.
Frequently Asked Questions
What is the difference between PT-141 and Melanotan II?
PT-141 (Bremelanotide) is a cyclic heptapeptide derived from Melanotan II research that selectively targets MC3R and MC4R receptors — the receptors responsible for sexual arousal and CNS effects. Melanotan II is a broader non-selective melanocortin agonist that hits MC1R, MC3R, MC4R, and MC5R, producing tanning (MC1R), appetite suppression (MC4R), sexual effects (MC3R/MC4R), and other systemic responses. PT-141 was developed specifically for sexual health research by removing the tanning and side-effect profile of Melanotan II.
Is PT-141 FDA approved?
Yes — PT-141 (as Vyleesi/bremelanotide) received FDA approval in June 2019 for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the only FDA-approved peptide for female sexual dysfunction. Melanotan II has never been FDA approved for any indication.
Which is better for sexual health research — PT-141 or Melanotan II?
PT-141 is the superior compound for sexual health research due to its receptor selectivity (MC3R/MC4R without MC1R activation), its FDA approval path that validated the mechanism, and its extensive clinical trial data including Phase 3 trials in both female and male sexual dysfunction. Melanotan II produces sexual effects at lower doses but with a much broader side-effect profile from non-selective melanocortin receptor activation.
Does Melanotan II cause tanning?
Yes — Melanotan II activates MC1R receptors on melanocytes, stimulating melanogenesis and increasing skin melanin content. This produces systemic tanning regardless of UV exposure, as well as darkening of existing moles and nevi. PT-141 was specifically designed to lack this MC1R activity, making it neutral for tanning.
Research use only. All products sold by JA Performance are strictly for laboratory and in vitro research purposes. Not for human consumption, medical use, or veterinary use.